CiloTax StentTM - summitMD.com

More documents

Recommendations

Info

Histopathologic Examination Results
Results BMS (n=3) Cilotax stent (n=4) P value EEL area, mm 2 7.40 ± 2.50 7.17 ± 1.01 0.872 IEL area, mm 2 6.32 ± 2.17 5.82 ± 1.23 0.710 Stent area, mm 2 6.32 ± 2.17 5.53 ± 0.58 0.508 Lumen area, mm 2 3.80 ± 1.34 4.34 ± 0.66 0.504 Intimal area, mm 2 2.52 ± 0.98 1.48 ± 0.63 0.144 Medial area, mm 2 1.08 ± 0.33 1.35 ± 0.32 0.320 Stenosis, % 38.61 ± 5.35 24.91 ± 5.26 0.020 Intimal thickness, mm 0.39 ± 0.09 0.21 ± 0.04 0.019 Injury score 0.59 ± 0.39 0.33 ± 0.24 0.478
Page 1 and 2: CiloTax Stent TM Dual Drug-eluting
Page 3 and 4: Moving Forward Co-drug Eluting Sten
Page 5 and 6: A Potent Anti-platelet Agent Effect
Page 7 and 8: Anti-restenotic Effect DECLARE - Lo
Page 9 and 10: The Ideal Combination? Cilotax TM S
Page 11 and 12: Cilotax Stent TM Polymer & Drugs Po
Page 13 and 14: Safety and Efficacy of the Cilotax
Page 15 and 16: Animal Preparation • Juvenile swi
Page 17 and 18: Analysis • Angiography and IVUS:
Page 19 and 20: Results 3.0 18mm Cilotax BMS 4 week
Page 21: IVUS Analysis at Follow-Up (n=7) BM
Page 25 and 26: Results Inflammatory Response BMS (
Page 27 and 28: Clinical Study Efficacy and Safety
Page 29 and 30: Objectives • to assess safety and
Page 31 and 32: Study Endpoints • Statistics - a

CiloTax StentTM - summitMD.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?